These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

765 related items for PubMed ID: 12384531

  • 1. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E.
    Cancer Res; 2002 Oct 15; 62(20):5727-35. PubMed ID: 12384531
    [Abstract] [Full Text] [Related]

  • 2. Combined antiangiogenic and immune therapy of prostate cancer.
    Huang X, Raskovalova T, Lokshin A, Krasinskas A, Devlin J, Watkins S, Wolf SF, Gorelik E.
    Angiogenesis; 2005 Oct 15; 8(1):13-23. PubMed ID: 16132614
    [Abstract] [Full Text] [Related]

  • 3. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.
    Sturmhoefel K, Lee K, Gray GS, Thomas J, Zollner R, O'Toole M, Swiniarski H, Dorner A, Wolf SF.
    Cancer Res; 1999 Oct 01; 59(19):4964-72. PubMed ID: 10519410
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T, Martuza RL, Dallman MJ, Rabkin SD.
    Cancer Res; 2001 Jan 01; 61(1):153-61. PubMed ID: 11196154
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
    Hiraoka S, Takeuchi N, Bian Y, Nakahara H, Kogo M, Dunussi-Joannopoulos K, Wolf S, Ono S, Fujiwara H.
    Int Immunol; 2005 Aug 01; 17(8):1071-9. PubMed ID: 16027141
    [Abstract] [Full Text] [Related]

  • 10. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
    Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B.
    Cancer Chemother Pharmacol; 2005 Dec 01; 56(6):569-77. PubMed ID: 16001166
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
    Liu LL, Smith MJ, Sun BS, Wang GJ, Redmond HP, Wang JH.
    Ann Surg Oncol; 2009 May 01; 16(5):1403-11. PubMed ID: 19263173
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.